4d pharma (FRA:4DY) Gross-Profit-to-Asset % : 1.29% (As of Dec. 2021)

View and export this data going back to 2020. Start your Free Trial

What is 4d pharma Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. 4d pharma's annualized Gross Profit for the quarter that ended in Dec. 2021 was €0.68 Mil. 4d pharma's average Total Assets over the quarter that ended in Dec. 2021 was €53.00 Mil. Therefore, 4d pharma's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2021 was 1.29%.

4d pharma Gross-Profit-to-Asset % Historical Data

The historical data trend for 4d pharma's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4d pharma Gross-Profit-to-Asset % Chart

4d pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

0.51

1.56

1.37

4d pharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21
Gross-Profit-to-Asset %	Get a 7-Day Free Trial											1.15	1.51	1.37	1.14	1.29

Competitive Comparison of 4d pharma's Gross-Profit-to-Asset %

For the Biotechnology subindustry, 4d pharma's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

4d pharma's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 4d pharma's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where 4d pharma's Gross-Profit-to-Asset % falls into.

4d pharma Gross-Profit-to-Asset % Calculation

4d pharma's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2021 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2021 )	/	( (Total Assets (A: Dec. 2020 )	+	Total Assets (A: Dec. 2021 ))	/ count )
	=	0.614	/	( (39.134	+	50.534)	/ 2 )
	=	0.614	/	44.834
	=	1.37 %

4d pharma's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2021 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2021 )	/	( (Total Assets (Q: Jun. 2021 )	+	Total Assets (Q: Dec. 2021 ))	/ count )
	=	0.682	/	( (55.466	+	50.534)	/ 2 )
	=	0.682	/	53
	=	1.29 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2021) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

4d pharma Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of 4d pharma's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

4d pharma (FRA:4DY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4d pharma PLC (FRA:4DY) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

9 Bond Court, Fifth Floor, Leeds, GBR, LS1 2JZ

Website

https://www.4dpharmaplc.com

4d pharma PLC and its subsidiaries are in the business of research and development and production of live biotherapeutic products. The company develops biotherapeutic products for diseases such as cancer, asthma, autism, and autoimmune conditions such as arthritis and multiple sclerosis. Its developing science includes Live biotherapeutics, Microbiome, MicroRx, MicroDx, and others.

4d pharma (FRA:4DY) Headlines

No Headlines